Tata group to launch India’s first low-cost Covid-19 test ‘Feluda’

wayne


The Drugs Controller General of India has approved of the commercial launch of ‘Feluda’, the Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) Covid-19 test, the Council of Scientific and Industrial Research (CSIR) said recently.


This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus, CSIR said in a statement.



The Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests with quicker turnaround time, less expensive equipment and better ease of use. CRISPR is a genome editing technology to diagnose diseases.

Next Post

EPFO records 845,000 new enrolments in July, up from 482,000 in June

Net new enrolments with retirement fund body EPFO rose to 8.45 lakh in July from 4.82 lakh in June 2020, according to its latest payroll data, providing a perspective on employment in the formal sector amid the COVID-19 crisis. Provisional payroll data released by the EPFO […]

Subscribe Now